Skip to main content

DNA electrotransfer of plasmids coding for antiangiogenic factors as a proof of principle of non-viral gene therapy for the treatment of skin disease

Objective

The ANGIOSKIN consortium wants to bring the proof of concept that therapeutic genes can be safely delivered to skin by DNA electrotransfer (electrogenetherapy) in order to prevent or to treat acquired or inherited skin diseases. ANGIOSKIN proposal is based on the results of the 5th FP CLINIPORATOR project (analysis of the mechanisms of DNA electrotransfer and elaboration of a CE labelled pulse generator) and of the 5th FP ESOPE project (preparation of the Standard Operating Procedures of Electrogenetherapy, electrotransferring a reporter gene in humans), and on a proprietary gene coding for a potent human antiangiogenic factor. This factor is the disintegrin fragment of the Metargidin, also referred as AMD-15 (MDC 15 in mouse), and it specifically binds to t he avß3 and a5ß1 integrins involved in angiogenic processes. ANGIOSKIN consortium will: - Electrotransfer the proprietary therapeutic antiangiogenesis gene to melanoma cutaneous metastasis in humans, using the procedures validated in ESOPE project, to show its clinical efficacy; non invasive biophysical methods (e.g. Doppler ultrasonography) will be used to monitor the angioangiogenic effects; - Develop new specific electrodes for skin lesions treatment, based on arrays of hollow microneedles allowing both DNA and electric pulse delivery, and requiring the use of micromechanics ans microfluidics techniques; - Validate the electrodes (safety, efficacy) on normal skin in animals, and analyse the effects of the electrotransfer of the antioangiogenetic factor on models of skin disease related to excessive angiogenesis (models of psoriasis), using non nonvasive biophysical as well as histological methods to follow changes in the vascularization of the lesion; - Finally, electrotransfer the therapeutic gene to a be nign lesion (psoriasis) in humans as a proof of concept of the use of non-viral gene therapy to treat acquired or inherited skin diseases.

Call for proposal

FP6-2003-LIFESCIHEALTH-I
See other projects for this call

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - DÉLÉGATION ILE-DE-FRANCE EST
Address
Tour Europa 126
Thiais
France

Participants (9)

IGEA S.R.L.
Italy
Address
Via Parmenide 10/A
Carpi (Mo)
INSTITUT GUSTAVE-ROUSSY
France
Address
39 Rue Camille Desmoulins
Villejuif
DEPARTMENT OF ONCOLOGY, HERLEV HOSPITAL
Denmark
Address
Herlev Ringvej 75
Herlev
BAYERISCHE JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG
Germany
Address
Sanderring 2
Wuerzburg
BIOALLIANCE PHARMA SA
France
Address
59 Boulevard General Martial Valin
Paris
UNIVERSITY OF LJUBLJANA, FACULTY OF ELECTRICAL ENGINEERING
Slovenia
Address
Trzaska 25
Ljubljana
DEPT. OF DERMATOLOGY, GENTOFTE UNIVERSITY HOSPITAL, COPENHAGEN, DENMARK
Denmark
Address
Niels Andersens Vej 65
Hellerup
UNIVERSITÄTSMEDIZIN GÖTTINGEN - GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN - STIFTUNG ÖFFENTLICHEN RECHTS
Germany
Address
Robert-koch-str. 40
Göttingen
UNIVERSITÉ CATHOLIQUE DE LOUVAIN
Belgium
Address
Place De L'université 1'
Louvain-la-neuve